Remarkably, the highest anticancer impact was reached in the most difficult-to-treat, densely packed established tumors, rather than on isolated tumor cells, whereby 2EF outcompeted all benchmark anti-Trop-2 mAb that were tested. The gene discussed is TACSTD2; the disease is neoplasm.